Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13) (original) (raw)

Vanesa-Sindi Ivanova hasn't uploaded this paper.

Create a free Academia account to let Vanesa-Sindi Ivanova know you want this paper to be uploaded.

Ask for this paper to be uploaded.